License to Kill Tumors: How Much Hope is Justified for Trail?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|7|16|1689-1701

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.7, Iss.16, 2001-11, pp. : 1689-1701

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How Much Is Too Much?

By COLEMAN WILLIAM P.  

Dermatologic Surgery, Vol. 22, Iss. 11, 1996-11 ,pp. : 978-978

Elsevier

Access to resources Recommend Favorite

Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?

By  

Current Clinical Pharmacology, Vol. 10, Iss. 4, 2015-10 ,pp. : 311-320

Bentham Science Publishers

Access to resources Recommend Favorite

TRAIL: A Sword for Killing Tumors

By  

Current Medicinal Chemistry, Vol. 17, Iss. 29, 2010-10 ,pp. : 3309-3317

Bentham Science Publishers

Access to resources Recommend Favorite

Exercise and vascular function: how much is too much?

By Durand Matthew J.   Gutterman David D.  

Canadian Journal of Physiology and Pharmacology, Vol. 92, Iss. 7, 2014-01 ,pp. : 551-557

NRC Research Press

Access to resources Recommend Favorite

Commentary: How Much Is Too Much? Tourniquets and Digital Ischemia

By Jellinek Nathaniel J.  

Dermatologic Surgery, Vol. 39, Iss. 4, 2013-04 ,pp. : 593-595

Elsevier

Access to resources Recommend Favorite